Fig. 3.
The sensitivity of TB incidence and TB-related mortality at 2050 to assumptions about interventions started in 2015. (A) Neonatal vaccination with basic pre-exposure vaccine varying VEP, the reduction in probability of becoming a fast progressor, from 0 to 100%. (B) Novel NAAT diagnostic, varying the proportion of reduction in average duration of infectiousness from 0 to 1.0 (C) Varying the treatment success proportion, the effect of novel active-disease treatment regimens from the current 0.84 to 1.00.